[go: up one dir, main page]

CL2014000574A1 - Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. - Google Patents

Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.

Info

Publication number
CL2014000574A1
CL2014000574A1 CL2014000574A CL2014000574A CL2014000574A1 CL 2014000574 A1 CL2014000574 A1 CL 2014000574A1 CL 2014000574 A CL2014000574 A CL 2014000574A CL 2014000574 A CL2014000574 A CL 2014000574A CL 2014000574 A1 CL2014000574 A1 CL 2014000574A1
Authority
CL
Chile
Prior art keywords
aßtcr
binds
complex
human
monoclonal antibody
Prior art date
Application number
CL2014000574A
Other languages
English (en)
Inventor
Daniel Snell
Andreas Menrad
Gina Lacorcia
Huawei Qiu
Clark Pan
Benjamin Kebble
Srinivas Shankara
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000574(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2014000574A1 publication Critical patent/CL2014000574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2014000574A 2011-09-12 2014-03-10 Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. CL2014000574A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161533510P 2011-09-12 2011-09-12

Publications (1)

Publication Number Publication Date
CL2014000574A1 true CL2014000574A1 (es) 2015-04-10

Family

ID=46851393

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000574A CL2014000574A1 (es) 2011-09-12 2014-03-10 Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CL2017001730A CL2017001730A1 (es) 2011-09-12 2017-06-29 Anticuerpo anti - alfabeta tcr

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017001730A CL2017001730A1 (es) 2011-09-12 2017-06-29 Anticuerpo anti - alfabeta tcr

Country Status (34)

Country Link
US (3) US10017573B2 (es)
EP (1) EP2755999B1 (es)
JP (2) JP6096196B2 (es)
KR (1) KR20140072092A (es)
CN (3) CN119119269A (es)
AU (2) AU2012307816C1 (es)
BR (2) BR122021001193B1 (es)
CA (1) CA2847949C (es)
CL (2) CL2014000574A1 (es)
CO (1) CO6930307A2 (es)
CR (1) CR20140127A (es)
DK (1) DK2755999T3 (es)
DO (1) DOP2014000052A (es)
EC (1) ECSP14013307A (es)
ES (1) ES2667893T3 (es)
GT (1) GT201400045A (es)
HU (1) HUE037470T2 (es)
IL (2) IL231304B (es)
LT (1) LT2755999T (es)
MA (1) MA35711B1 (es)
MX (2) MX355735B (es)
MY (1) MY173924A (es)
NI (1) NI201400019A (es)
PE (1) PE20141548A1 (es)
PH (1) PH12014500408A1 (es)
PL (1) PL2755999T3 (es)
PT (1) PT2755999T (es)
RU (2) RU2017129721A (es)
SG (2) SG11201400126PA (es)
TN (1) TN2014000107A1 (es)
TW (1) TWI593706B (es)
UA (1) UA115533C2 (es)
UY (1) UY34317A (es)
WO (1) WO2013037484A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
PL2895513T3 (pl) * 2012-09-12 2018-11-30 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
SG10201803473WA (en) * 2013-10-30 2018-06-28 Genzyme Corp Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CA2987877A1 (en) * 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
LT3652215T (lt) 2017-07-14 2021-05-25 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
MA55529A (fr) * 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN113122504A (zh) * 2019-12-30 2021-07-16 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
JP2023516538A (ja) * 2019-12-30 2023-04-20 博雅▲緝▼因（北京）生物科技有限公司 Ｕｃａｒｔ細胞を精製する方法及び応用
CN113122503B (zh) * 2019-12-30 2022-10-11 博雅缉因（北京）生物科技有限公司 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用
GB2609554B (en) * 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN113088495B (zh) * 2020-01-09 2024-08-16 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
CN119233999A (zh) * 2022-05-25 2024-12-31 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6465612B1 (en) 1998-09-23 2002-10-15 The Regents Of The University Of California Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1110322C (zh) 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7657380B2 (en) * 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
JP4768439B2 (ja) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
RU2392324C2 (ru) * 2003-09-18 2010-06-20 Симфоген А/С Способ связывания интересующих последовательностей
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7001978B2 (en) 2003-11-19 2006-02-21 Xerox Corporation Unsaturated ester substituted polymers with reduced halogen content
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
ATE437184T1 (de) 2004-01-12 2009-08-15 Applied Molecular Evolution Varianten der fc-region
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1745141B2 (en) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2581505A1 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
CA2602777C (en) * 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
DK1896071T3 (en) 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CZ2005627A3 (cs) 2005-10-03 2006-09-13 Flek@Jaroslav Zubní kartácek
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
JP5597793B2 (ja) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
JP2010512306A (ja) 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ES2673153T3 (es) 2007-01-09 2018-06-20 Biogen Ma Inc. Anticuerpos Sp35 y usos de los mismos
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
DK2205258T3 (en) 2007-09-28 2017-08-28 Janssen Biotech Inc Method and structural conformations of antibody preparations with increased resistance to proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5606916B2 (ja) 2007-10-19 2014-10-15 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
SG10201604336VA (en) * 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
DK2603528T3 (en) 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EA031874B1 (ru) 2011-03-11 2019-03-29 Амикус Терапьютикс, Инк. Способ лечения болезни фабри
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
PL2895513T3 (pl) 2012-09-12 2018-11-30 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
IL275376B2 (en) 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US10905678B2 (en) 2014-04-08 2021-02-02 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose

Also Published As

Publication number Publication date
US20180237522A1 (en) 2018-08-23
IL259826A (en) 2018-07-31
AU2017261557A1 (en) 2017-12-07
PL2755999T3 (pl) 2018-09-28
UA115533C2 (uk) 2017-11-27
CN119119269A (zh) 2024-12-13
IL231304A0 (en) 2014-04-30
ES2667893T3 (es) 2018-05-14
AU2017261557B2 (en) 2019-11-14
BR112014005644A2 (pt) 2017-03-28
RU2017129721A3 (es) 2019-02-06
MX355735B (es) 2018-04-27
CA2847949C (en) 2019-12-03
RU2630656C2 (ru) 2017-09-11
AU2012307816A8 (en) 2014-06-19
TN2014000107A1 (en) 2015-07-01
PH12014500408A1 (en) 2022-04-18
NI201400019A (es) 2014-10-10
US20220153841A1 (en) 2022-05-19
RU2017129721A (ru) 2019-02-06
EP2755999B1 (en) 2018-01-31
CO6930307A2 (es) 2014-04-28
MA35711B1 (fr) 2014-12-01
WO2013037484A2 (en) 2013-03-21
HK1199268A1 (en) 2015-08-07
DOP2014000052A (es) 2014-09-15
IL231304B (en) 2018-06-28
TWI593706B (zh) 2017-08-01
ECSP14013307A (es) 2015-04-30
DK2755999T3 (en) 2018-05-22
MX379660B (es) 2025-03-11
WO2013037484A3 (en) 2013-08-29
AU2012307816B2 (en) 2017-08-17
AU2012307816A1 (en) 2014-04-24
JP2017108752A (ja) 2017-06-22
CA2847949A1 (en) 2013-03-21
TW201313741A (zh) 2013-04-01
JP6599911B2 (ja) 2019-10-30
NZ717726A (en) 2017-11-24
JP2014527802A (ja) 2014-10-23
MX2014002963A (es) 2015-03-19
CR20140127A (es) 2014-08-20
CN104684930B (zh) 2019-04-26
KR20140072092A (ko) 2014-06-12
MY173924A (en) 2020-02-27
US11186638B2 (en) 2021-11-30
RU2014114527A (ru) 2015-10-20
EP2755999A2 (en) 2014-07-23
JP6096196B2 (ja) 2017-03-15
US10017573B2 (en) 2018-07-10
NZ623656A (en) 2016-04-29
CL2017001730A1 (es) 2018-03-16
UY34317A (es) 2013-02-28
LT2755999T (lt) 2018-05-10
AU2012307816C1 (en) 2017-12-07
BR122021001193B1 (pt) 2023-05-16
SG11201400126PA (en) 2014-03-28
PT2755999T (pt) 2018-05-14
SG10201601738UA (en) 2016-04-28
CN110272492A (zh) 2019-09-24
HUE037470T2 (hu) 2018-08-28
WO2013037484A8 (en) 2014-05-22
PE20141548A1 (es) 2014-11-18
US20150099861A1 (en) 2015-04-09
GT201400045A (es) 2015-07-29
CN104684930A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
DK4459282T3 (da) Monoklonalt interleukin-31-antistof
PL3789038T3 (pl) Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
BR112013022797A2 (pt) anticorpos anti-ctla4 humanizados
IL221408B (en) Monoclonal antibodies against c-met
DK3016681T3 (da) Humaniserede eller kimære CD3-antistoffer
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
BR112013032552A2 (pt) variantes de anticorpos monoclonais humanizados imunomoduladores
DK2521736T3 (da) Humaniserede antistoffer
EP3427721C0 (en) HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
IL229618B (en) Isolated antibody that binds fcrn
EP3029069A4 (en) Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
PL2970503T3 (pl) Przeciwciała monoklonalne przeciw-(+) --metamfetaminie
TH98689B (th) ฮิวแมไนซ์แอนติบอดีที่จดจำแอลฟา-ไซนูคลีน
NZ737925A (en) Monoclonal antibodies against c-met